129 related articles for article (PubMed ID: 12846439)
21. Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils.
Wallace JL; McKnight W; Wilson TL; Del Soldato P; Cirino G
Am J Physiol; 1997 Dec; 273(6):G1246-51. PubMed ID: 9435549
[TBL] [Abstract][Full Text] [Related]
22. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016).
Corazzi T; Leone M; Maucci R; Corazzi L; Gresele P
J Pharmacol Exp Ther; 2005 Dec; 315(3):1331-7. PubMed ID: 16144976
[TBL] [Abstract][Full Text] [Related]
23. Nitric oxide-releasing NSAIDs: a review of their current status.
Fiorucci S; Antonelli E; Burgaud JL; Morelli A
Drug Saf; 2001; 24(11):801-11. PubMed ID: 11665868
[TBL] [Abstract][Full Text] [Related]
24. Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia.
Derhaschnig U; Schweeger-Exeli I; Marsik C; Cardona F; Minuz P; Jilma B
Platelets; 2010; 21(5):320-8. PubMed ID: 20608787
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic effects of nitric oxide-aspirin hybrid drugs.
Turnbull CM; Rossi AG; Megson IL
Expert Opin Ther Targets; 2006 Dec; 10(6):911-22. PubMed ID: 17105376
[TBL] [Abstract][Full Text] [Related]
26. No-Aspirin (NCX 4016).
Mann NS
Gastroenterology; 2003 Dec; 125(6):1918-9. PubMed ID: 14727635
[No Abstract] [Full Text] [Related]
27. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.
Kodela R; Chattopadhyay M; Velázquez-Martínez CA; Kashfi K
Biochem Pharmacol; 2015 Dec; 98(4):564-72. PubMed ID: 26394025
[TBL] [Abstract][Full Text] [Related]
28. The effect of aspirin and two nitric oxide donors on the infarcted heart in situ.
Yamamoto T; Kakar NR; Vina ER; Johnson PE; Bing RJ
Life Sci; 2000 Jul; 67(7):839-46. PubMed ID: 10968413
[TBL] [Abstract][Full Text] [Related]
29. NO-NSAIDs: from inflammatory mediators to clinical readouts.
Fiorucci S; Antonelli E
Inflamm Allergy Drug Targets; 2006 Apr; 5(2):121-31. PubMed ID: 16613571
[TBL] [Abstract][Full Text] [Related]
30. Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans.
de la Cruz JP; Guerrero A; González-Correa JA; Márquez E; Nacle I; Sánchez de la Cuesta F
Eur J Clin Pharmacol; 2002 Jan; 57(11):775-80. PubMed ID: 11871383
[TBL] [Abstract][Full Text] [Related]
31. Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis.
Kato S; Suzuki K; Ukawa H; Komoike Y; Takeuchi K
Dig Dis Sci; 2001 Aug; 46(8):1690-9. PubMed ID: 11508669
[TBL] [Abstract][Full Text] [Related]
32. Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin.
Takeuchi K; Ukawa H; Konaka A; Kitamura M; Sugawa Y
J Pharmacol Exp Ther; 1998 Jul; 286(1):115-21. PubMed ID: 9655849
[TBL] [Abstract][Full Text] [Related]
33. Nitric oxide regulates immune cell bioenergetic: a mechanism to understand immunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs.
Fiorucci S; Mencarelli A; Distrutti E; Baldoni M; del Soldato P; Morelli A
J Immunol; 2004 Jul; 173(2):874-82. PubMed ID: 15240674
[TBL] [Abstract][Full Text] [Related]
34. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin.
Momi S; Emerson M; Paul W; Leone M; Mezzasoma AM; Del Soldato P; Page CP; Gresele P
Eur J Pharmacol; 2000 May; 397(1):177-85. PubMed ID: 10844112
[TBL] [Abstract][Full Text] [Related]
35. Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat.
Carini M; Aldini G; Orioli M; Piccoli A; Rossoni G; Maffei Facino R
Life Sci; 2004 May; 74(26):3291-305. PubMed ID: 15094329
[TBL] [Abstract][Full Text] [Related]
36. Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3.
Royle JS; Ross JA; Ansell I; Bollina P; Tulloch DN; Habib FK
J Urol; 2004 Jul; 172(1):338-44. PubMed ID: 15201807
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide-releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs.
Wallace JL; Pittman QJ; Cirino G
Agents Actions Suppl; 1995; 46():121-9. PubMed ID: 7610982
[TBL] [Abstract][Full Text] [Related]
38. The antiplatelet effects of a new nitroderivative of acetylsalicylic acid--an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production.
Lechi C; Andrioli G; Gaino S; Tommasoli R; Zuliani V; Ortolani R; Degan M; Benoni G; Bellavite P; Lechi A; Minuz P
Thromb Haemost; 1996 Nov; 76(5):791-8. PubMed ID: 8950792
[TBL] [Abstract][Full Text] [Related]
39. Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Pawlik M; Pajdo R; Kwiecien S; Ptak-Belowska A; Sliwowski Z; Mazurkiewicz-Janik M; Konturek SJ; Pawlik WW; Brzozowski T
J Physiol Pharmacol; 2011 Feb; 62(1):75-86. PubMed ID: 21451212
[TBL] [Abstract][Full Text] [Related]
40. Effects of inhaled nitric oxide compared with aspirin on platelet function in vivo in healthy subjects.
Albert J; Wallén NH; Bröijersén A; Frostell C; Hjemdahl P
Clin Sci (Lond); 1996 Aug; 91(2):225-31. PubMed ID: 8795448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
